African-American men tend to have poorer overall survival rates than Caucasian men after being treated for localized prostate cancer, a new study shows.
Tumor biology may affect response to kidney cancer treatment, study finds
In total, the investigators assessed data from 886 patients with advanced kidney cancer who were randomly assigned to receive avelumab plus axitinib or subitinib.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Treatment begins in study of gedatolisib plus darolutamide in mCRPC
The CELC-G-201 trial is assessing the safety, preliminary efficacy, and pharmacokinetics of gedatolisib plus darolutamide in mCRPC
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
FDA requests additional data regarding cefepime-taniborbactam for cUTI
The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.
Study launches of BNT316/ONC-392 plus radioligand therapy in mCRPC
In total, the phase 1/2 PRESERVE-006 trial is expected to enroll 144 patients across 20 clinical trial sites in the US.
2 Commerce Drive Cranbury, NJ 08512